Stock Analiz

BioCardia, Inc. BCDA

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$0.83Market cap $13M
Open the interactive analysis →

BioCardia, Inc. (BCDA) is a healthcare company listed in the US with a market value of about $13M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -260%.

About BioCardia

BioCardia is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $904000 in 2015 to $58000 in 2024, a decline of about 26.3% a year. It was profitable in 0 of the last 10 years in our data. Its share count fell by 62% over three years (buybacks).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health1/5
Shareholder returns1/5

Checks passed

  • More cash than debt, or low debt to equity
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B15.1
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-60.6%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-100.0%
Revenue growth (5 yrs, per year)-100.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-4562.5%
ROIC (5-yr avg.)-259.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$0$58000$477000$1M$1M$145000$710000$625000$479000$576000
Net income-$8M-$8M-$12M-$12M-$13M-$15M-$15M-$14M-$12M-$10M
Free cash flow-$7M-$8M-$10M-$11M-$10M-$12M-$10M-$11M-$9M—
EPS (diluted)$-1.23$-2.90$-8.19$-0.67$-0.75$-1.48$-2.61$-3.28$-2.90$-11.07
Net margin—-13700.0%-2425.8%-880.7%-1243.7%-10347.6%-2071.7%-2237.9%-2569.5%-1789.9%
ROIC-459.6%-353.5%—-144.1%-81.5%-62.0%-319.7%-293.8%-88.1%-29.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $15.50, 1765% above the current price; targets range from $6.00 to $25.00; the consensus rating is “Strong buy”; expected EPS is $-0.63 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does BioCardia pay a dividend?

Not currently.

Is BioCardia a good stock to buy?

We do not give buy or sell advice. BioCardia scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.